Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | BEGONIA: durvalumab combinations in advanced TNBC

Peter Schmid • 9 Dec 2021
SABCS 2021
Breast Cancer Antibodies Durvalumab Trastuzumab deruxtecan
BEGONIA

Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, discusses the BEGONIA study (NCT03742102), a Phsae Ib/II study of durvalumab combinations in locally advanced/metastatic triple-negative breast cancer (TNBC). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

More from Peter Schmid

4:20
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Peter Schmid • 22 Oct 2023
3:22
BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancer
Peter Schmid • 22 Oct 2023
3:07
Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALD
Peter Schmid • 9 Dec 2021
4:17
KEYNOTE-522: EFS sensitivity & subgroup analyses
Peter Schmid • 9 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals